膦甲酸钠与2'，3'-双脱氧肌苷或2'，3'-双脱氧胞苷联合对人免疫缺陷病毒分离株（包括对3'-叠氮-3'-脱氧胸苷耐药的分离株）的协同抑制作用。
Synergistic inhibition of human immunodeficiency virus isolates (including 3'-azido-3'-deoxythymidine-resistant isolates) by foscarnet in combination with 2',3'-dideoxyinosine or 2',3'-dideoxycytidine.
作者信息
Palmer S, Harmenberg J, Cox S
机构信息
Virology Department, Swedish Institute for Infectious Disease Control, Stockholm, Sweden.
出版信息
Antimicrob Agents Chemother. 1996 May;40(5):1285-8. doi: 10.1128/AAC.40.5.1285.
Abstract
The combinations of foscarnet plus 2',3'-dideoxyinosine and foscarnet plus 2',3'-dideoxycytidine synergistically inhibit the replication of human immunodeficiency virus type 1 isolates, including two 3'-azido-3'-deoxythymidine-resistant isolates. The combination of 2',3'-dideoxyinosine plus 2',3'-dideoxycytidine showed additive inhibition of the majority of the human immunodeficiency virus isolates tested. All three combinations showed pronounced antagonistic cytotoxicity and thus were less toxic to the growth of peripheral blood mononuclear cells than the separate drugs.
摘要
膦甲酸钠联合2′,3′-双脱氧肌苷以及膦甲酸钠联合2′,3′-双脱氧胞苷可协同抑制1型人类免疫缺陷病毒分离株的复制，包括两株对3′-叠氮-3′-脱氧胸苷耐药的分离株。2′,3′-双脱氧肌苷联合2′,3′-双脱氧胞苷对所检测的大多数人类免疫缺陷病毒分离株显示出相加抑制作用。所有这三种联合用药均表现出明显的拮抗细胞毒性，因此对外周血单个核细胞生长的毒性低于单独使用药物。
相似文献
1
Synergistic inhibition of human immunodeficiency virus isolates (including 3'-azido-3'-deoxythymidine-resistant isolates) by foscarnet in combination with 2',3'-dideoxyinosine or 2',3'-dideoxycytidine.膦甲酸钠与2'，3'-双脱氧肌苷或2'，3'-双脱氧胞苷联合对人免疫缺陷病毒分离株（包括对3'-叠氮-3'-脱氧胸苷耐药的分离株）的协同抑制作用。
Antimicrob Agents Chemother. 1996 May;40(5):1285-8. doi: 10.1128/AAC.40.5.1285.
2
Multiple-drug-resistant mutants of feline immunodeficiency virus selected with 2',3'-dideoxyinosine alone and in combination with 3'-azido-3'-deoxythymidine.单独使用2',3'-双脱氧肌苷以及与3'-叠氮-3'-脱氧胸苷联合使用时筛选出的猫免疫缺陷病毒多药耐药突变体
Antimicrob Agents Chemother. 1994 Apr;38(4):861-4. doi: 10.1128/AAC.38.4.861.
3
Combinations of 3'-azido-3'-deoxythymidine (zidovudine) and phosphonoformate (foscarnet) against human immunodeficiency virus type 1 and cytomegalovirus replication in vitro.3'-叠氮-3'-脱氧胸苷（齐多夫定）与膦甲酸盐（膦甲酸）联合用于抗1型人类免疫缺陷病毒及体外巨细胞病毒复制的研究
Antimicrob Agents Chemother. 1989 May;33(5):663-9. doi: 10.1128/AAC.33.5.663.
4
Human immunodeficiency virus type 1 drug susceptibility during zidovudine (AZT) monotherapy compared with AZT plus 2',3'-dideoxyinosine or AZT plus 2',3'-dideoxycytidine combination therapy. The protocol 34,225-02 Collaborative Group.与齐多夫定（AZT）联合2',3'-双脱氧肌苷或AZT联合2',3'-双脱氧胞苷联合疗法相比，齐多夫定（AZT）单药治疗期间1型人类免疫缺陷病毒的药物敏感性。方案34225 - 02协作组。
J Virol. 1996 Sep;70(9):5922-9. doi: 10.1128/JVI.70.9.5922-5929.1996.
5
Inhibition of human immunodeficiency virus in vitro by combinations of 3'-azido-3'-deoxythymidine and foscarnet.3'-叠氮-3'-脱氧胸苷与膦甲酸联合用药在体外对人类免疫缺陷病毒的抑制作用
Antimicrob Agents Chemother. 1989 May;33(5):778-80. doi: 10.1128/AAC.33.5.778.
6
Comparison of the sensitivities of primary isolates of HIV type 2 and HIV type 1 to antiviral drugs and drug combinations.2型和1型人类免疫缺陷病毒原始分离株对抗病毒药物及药物组合的敏感性比较。
AIDS Res Hum Retroviruses. 1994 Dec;10(12):1725-9. doi: 10.1089/aid.1994.10.1725.
7
Synergistic inhibition of replication of human immunodeficiency virus type 1, including that of a zidovudine-resistant isolate, by zidovudine and 2',3'-dideoxycytidine in vitro.齐多夫定与2',3'-双脱氧胞苷在体外对人免疫缺陷病毒1型（包括对齐多夫定耐药的毒株）复制的协同抑制作用。
Antimicrob Agents Chemother. 1992 Jul;36(7):1559-62. doi: 10.1128/AAC.36.7.1559.
8
Two-drug combinations of zidovudine, didanosine, and recombinant interferon-alpha A inhibit replication of zidovudine-resistant human immunodeficiency virus type 1 synergistically in vitro.齐多夫定、去羟肌苷与重组α-A干扰素的两药联合体外协同抑制齐多夫定耐药的1型人类免疫缺陷病毒复制。
J Infect Dis. 1991 Oct;164(4):646-55. doi: 10.1093/infdis/164.4.646.
9
Disparate actions of hydroxyurea in potentiation of purine and pyrimidine 2',3'-dideoxynucleoside activities against replication of human immunodeficiency virus.羟基脲在增强嘌呤和嘧啶2',3'-二脱氧核苷抗人免疫缺陷病毒复制活性方面的不同作用。
Proc Natl Acad Sci U S A. 1995 Aug 29;92(18):8333-7. doi: 10.1073/pnas.92.18.8333.
10
Anti-HIV activity of dideoxynucleosides, foscarnet and fusidic acid is potentiated by human leukocyte interferon in blood-derived macrophages.
Chemotherapy. 1994 May-Jun;40(3):201-8. doi: 10.1159/000239193.
引用本文的文献
1
Hydroxyurea enhances the activities of didanosine, 9-[2-(phosphonylmethoxy)ethyl]adenine, and 9-[2-(phosphonylmethoxy)propyl]adenine against drug-susceptible and drug-resistant human immunodeficiency virus isolates.羟基脲可增强去羟肌苷、9-[2-(膦酰甲氧基)乙基]腺嘌呤及9-[2-(膦酰甲氧基)丙基]腺嘌呤对药物敏感及耐药的人类免疫缺陷病毒分离株的活性。
Antimicrob Agents Chemother. 1999 Aug;43(8):2046-50. doi: 10.1128/AAC.43.8.2046.
2
Highly drug-resistant HIV-1 clinical isolates are cross-resistant to many antiretroviral compounds in current clinical development.高度耐药的HIV-1临床分离株对目前临床研发中的许多抗逆转录病毒化合物具有交叉耐药性。
AIDS. 1999 Apr 16;13(6):661-7. doi: 10.1097/00002030-199904160-00006.
3
Zalcitabine. An update of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of HIV infection.扎西他滨。其药效学和药代动力学特性以及在治疗HIV感染中的临床疗效的最新情况。
Drugs. 1997 Jun;53(6):1054-80. doi: 10.2165/00003495-199753060-00009.
本文引用的文献
1
Intracellular activation and cytotoxicity of three different combinations of 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosine.
AIDS Res Hum Retroviruses. 1995 Oct;11(10):1227-33. doi: 10.1089/aid.1995.11.1227.
2
Nucleoside analogs: similarities and differences.核苷类似物：异同之处
Clin Infect Dis. 1993 Feb;16 Suppl 1:S7-15. doi: 10.1093/clinids/16.supplement_1.s7.
3
A dose-ranging study of daily maintenance intravenous foscarnet therapy for cytomegalovirus retinitis in AIDS.艾滋病患者巨细胞病毒性视网膜炎每日维持性静脉注射膦甲酸钠治疗的剂量范围研究。
J Infect Dis. 1993 Aug;168(2):444-8. doi: 10.1093/infdis/168.2.444.
4
Comparison of mitochondrial morphology, mitochondrial DNA content, and cell viability in cultured cells treated with three anti-human immunodeficiency virus dideoxynucleosides.
Antimicrob Agents Chemother. 1994 Aug;38(8):1824-8. doi: 10.1128/AAC.38.8.1824.
5
Foscarnet for suppression of human immunodeficiency virus replication.膦甲酸钠用于抑制人类免疫缺陷病毒复制。
Antimicrob Agents Chemother. 1994 Mar;38(3):604-7. doi: 10.1128/AAC.38.3.604.
6
Comparison of the sensitivities of primary isolates of HIV type 2 and HIV type 1 to antiviral drugs and drug combinations.2型和1型人类免疫缺陷病毒原始分离株对抗病毒药物及药物组合的敏感性比较。
AIDS Res Hum Retroviruses. 1994 Dec;10(12):1725-9. doi: 10.1089/aid.1994.10.1725.
7
Effect of resistance on combination chemotherapy for human immunodeficiency virus infection.
Adv Enzyme Regul. 1993;33:27-36. doi: 10.1016/0065-2571(93)90007-z.
8
Foscarnet. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections.膦甲酸钠。对其在免疫功能低下的病毒感染患者中的抗病毒活性、药代动力学特性及治疗用途的重新评估。
Drugs. 1994 Aug;48(2):199-226. doi: 10.2165/00003495-199448020-00007.
9
Zidovudine treatment results in the selection of human immunodeficiency virus type 1 variants whose genotypes confer increasing levels of drug resistance.
J Gen Virol. 1994 Feb;75 ( Pt 2):341-51. doi: 10.1099/0022-1317-75-2-341.
10
Antiviral effects of phosphonoformate (PFA, foscarnet sodium).膦甲酸（PFA，膦甲酸钠）的抗病毒作用。
Pharmacol Ther. 1982;19(3):387-415. doi: 10.1016/0163-7258(82)90074-2.
Zotero 插件